Case Study 1: Operation Warp Speed and the COVID-19 Vaccine Rollout (2020–2021)

The Case in One Paragraph

In May 2020, the Trump administration launched Operation Warp Speed (OWS), a public-private partnership to develop, manufacture, and distribute COVID-19 vaccines on a timeline that was, by historical standards, impossible. The federal government committed approximately $18 billion over the next eight months, structured the regulatory and procurement pathways to compress what normally took ten years into eleven months, and underwrote at-risk manufacturing scale-up before any vaccine had received emergency authorization. By December 14, 2020 — 251 days after a U.S. national emergency was declared — the first FDA-authorized Pfizer-BioNTech vaccine doses were being administered to American health-care workers. By the end of February 2021, three vaccines (Pfizer-BioNTech, Moderna, and Johnson & Johnson) had received Emergency Use Authorization. By the end of June 2021, more than 153 million Americans (roughly 46 percent of the U.S. population) had received at least one dose. The CDC's modeling later estimated that the U.S. vaccine campaign prevented approximately 3.2 million deaths and 18.5 million hospitalizations during 2021 alone.¹

The Institutional Actors

OWS was an unusual federal enterprise because it cut across normally siloed agencies. The principal institutional actors were:

• The Department of Health and Human Services (HHS), the umbrella department, with Secretary Alex Azar overseeing the operation politically.
• The Biomedical Advanced Research and Development Authority (BARDA), an HHS subagency that funded vaccine candidates' development through milestone-based contracts.
• The Food and Drug Administration (FDA), which retained independent authority over vaccine authorization but worked with manufacturers in real time on trial design and rolling submission of data.
• The Centers for Disease Control and Prevention (CDC), which led national distribution planning through its Advisory Committee on Immunization Practices (ACIP) and its established public-health infrastructure.
• The National Institutes of Health (NIH), which had conducted the Moderna vaccine's foundational research at the Vaccine Research Center, in partnership with Moderna.
• The Department of Defense (DoD), which contributed General Gustave Perna to lead OWS logistics and provided supply-chain expertise from its experience moving complex materiel.
• The U.S. Army Materiel Command, which structured the cold-chain distribution networks for the ultra-cold-storage Pfizer vaccine.
• The Federal Emergency Management Agency (FEMA), which ran the initial distribution of vaccines to states under National Response Framework protocols.
• State health departments and local health systems, which administered roughly 70 percent of doses in the first six months.

This is, in itself, a useful illustration of how American government works: a major federal initiative typically requires a half-dozen or more agencies, with overlapping but distinct authorities, to function in coordination. OWS had a single political head (Azar / Perna), but the actual work was distributed.

Timeline

• January 21, 2020: First confirmed U.S. case of COVID-19 (Snohomish County, Washington).
• March 13, 2020: National emergency declared by presidential proclamation.
• March 27, 2020: Coronavirus Aid, Relief, and Economic Security (CARES) Act signed into law (Public Law 116–136), authorizing $2.2 trillion in pandemic response, including BARDA funding for vaccine development.
• April 29, 2020: First conversations between HHS and DoD about a coordinated vaccine acceleration program.
• May 15, 2020: Operation Warp Speed publicly announced.
• July 27, 2020: Moderna Phase 3 trial begins, with NIH-NIAID partnership.
• December 11, 2020: FDA grants Emergency Use Authorization to the Pfizer-BioNTech vaccine.
• December 14, 2020: First doses administered (a New York City ICU nurse, Sandra Lindsay, is widely reported as the first non-trial American to receive an authorized vaccine).
• December 18, 2020: FDA grants EUA to the Moderna vaccine.
• January 20, 2021: Biden administration takes office. The new administration retains the OWS distribution architecture, though it rebrands and restructures the political leadership and significantly expands federal involvement in vaccination sites.
• February 27, 2021: Johnson & Johnson vaccine receives EUA.
• April 19, 2021: All Americans 16 and older become eligible for vaccination.
• By July 4, 2021: 67 percent of U.S. adults have received at least one dose.

What Worked

Several things, by historical standards, worked extraordinarily well.

First, the public-private partnership structure allowed the federal government to absorb financial risk in a way private companies could not. BARDA's milestone-based contracts paid manufacturers for progress, not products: a vaccine candidate received funding to scale up manufacturing capacity before it had been proven safe and effective. This meant that on the day a vaccine received authorization, manufacturing had already been built out — there was no months-long delay to spin up factories. Without federal underwriting, no rational pharmaceutical company would have made these capital commitments at risk.

Second, the FDA preserved its scientific independence while compressing timelines. The agency held to its statutory standards — safety, efficacy, manufacturing quality — but worked in real time with manufacturers on trial design, accepted rolling submissions of data, and prioritized review. The result was authorization in months rather than years, without (according to subsequent peer-reviewed analyses) any meaningful compromise of the underlying scientific rigor.²

Third, the DoD-led logistics architecture worked. The Army Materiel Command's experience with complex temperature-controlled global supply chains was, it turned out, directly applicable to moving cold-chain vaccines from manufacturers to all 50 states, plus the District of Columbia and territories, in less than 72 hours from the moment FDA authorized release. This is not a routine federal capability; it is a specific institutional asset built up over decades of military logistics work.

Fourth, the political leadership of the operation, across two administrations, did not interfere with the scientific reviews. There were public-relations frictions (members of the Trump administration publicly pressured the FDA at various points to authorize candidates faster; senior FDA officials — most notably FDA Commissioner Stephen Hahn and Acting Commissioner Janet Woodcock — pushed back). But on the substance, the FDA's authorization decisions were made by career scientists on the basis of clinical-trial data, and the Biden administration, when it took office, did not unwind the OWS structure.

What Was Imperfect

Even successes have failures embedded in them. OWS had several.

The initial distribution to states in December 2020 and January 2021 was uneven: some states had robust public-health infrastructures and rolled out efficiently (West Virginia, for example, was widely lauded for an early successful campaign that leveraged its network of independent pharmacies), while others struggled with sign-up systems, eligibility prioritization, and the sheer logistics of running mass-vaccination sites. Federal involvement in actual administration was initially limited; the Biden administration substantially expanded it, opening federal vaccination sites at sports stadiums and convention centers in February and March 2021.

The Johnson & Johnson vaccine, after early enthusiasm, was paused in April 2021 over concerns about a rare but serious clotting disorder. The pause itself was an example of safety surveillance functioning correctly, but the public-communication challenges of explaining "this is a one-in-a-million risk that has caused us to pause distribution" undermined some confidence in the broader vaccination effort.

Vaccine hesitancy proved more persistent than initial models predicted. Despite vaccines being free, widely available by spring 2021, and supported by employers, schools, and most major institutions, full vaccination rates plateaued in the U.S. at roughly 70 percent of eligible adults — substantially below the 85 percent or higher many epidemiologists believed necessary for population-level immunity. The political coding of vaccination became a significant predictor of uptake, with self-identified Republicans having lower vaccination rates than self-identified Democrats throughout the campaign — a polarization pattern that public-health officials of both parties found troubling and that the chapter on Public Opinion (Chapter 18) will return to.

Why This Case Matters for Chapter 1

OWS is a useful counterweight to the cynical framing that "government can't do anything." A federal government routinely described as gridlocked, bureaucratic, and slow delivered, in eleven months, two highly effective vaccines and the logistical architecture to distribute them to every state in the country. The cost was significant; the speed was historic; the lives saved were measured in millions.

It is also a case study in how American institutions actually work when they work: not through a single charismatic leader or a single agency, but through coordinated action across multiple departments, levels of government, public and private actors, and (crucially) two consecutive administrations of opposing parties that disagreed about almost everything except the importance of the vaccine effort. The transition from Trump-era OWS to Biden-era vaccination distribution was one of the smoother handoffs in modern presidential history precisely because the underlying institutional architecture had been built durably enough to survive a change of partisan leadership.

This is theme 6 ("institutions shape behavior") in action. The architects of OWS were political appointees of one party; the executors of the rollout in 2021 were political appointees of the other; the institutional capacity that made it possible — career scientists at FDA, NIH, and CDC; logistics planners at DoD; public-health officers at every level — was largely partisan-neutral. The system worked because the institutions were robust.

It is also theme 2 ("gap between how government is supposed to work and how it actually works") in action — but in the positive direction. The textbook story of how the FDA approves drugs (10-year average, sequential review, formal advisory committee processes) was compressed because the institutions adapted to an emergency. Sometimes the gap between design and reality runs toward better outcomes than the formal process would have produced.

Discussion Questions

1. What features of the federal government's structure made OWS possible? What features almost prevented it? Identify at least one of each.

2. Operation Warp Speed required the federal government to underwrite manufacturing risk that private firms would not accept. Steel-man both: (a) the case that this is exactly the kind of public investment markets cannot produce, and government should make more such investments routinely; and (b) the case that this was an exceptional response to an exceptional crisis, and routine federal underwriting of private-sector research and manufacturing risks would produce worse outcomes (cronyism, capture, misallocation) than benefits.

3. Vaccination uptake in the United States plateaued at a level below what public-health officials of both parties believed necessary. Was this a failure of government, of public communication, of partisan media, of personal liberty (in the sense that some Americans simply chose not to be vaccinated, as is their constitutional right), or of some combination? Defend your answer.

4. Compare OWS to the case of the Healthcare.gov launch (Case Study 2). Both involved technology-intensive federal initiatives; one largely succeeded and one largely failed. What can we learn from the comparison?

5. Several public-health scholars argue that OWS demonstrates the unique capabilities of the U.S. federal government and should serve as a template for "moonshot" initiatives in cancer treatment, climate adaptation, and pandemic preparedness. Several free-market scholars argue that OWS is not generalizable — that pandemics create a uniquely high willingness on all sides to relax normal constraints, and that routine federal "moonshots" are far more likely to fail. Which position do you find more persuasive, and why?